Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the clinical and commercial development of innovative products and therapeutics that meet the needs of pain management practitioners and their patients. Our primary focus lies in the development of non-opioid products for meeting the needs of under served patients with back pain. We believe we have the technology to improve products' efficacy and safety and make a critical difference in the treatment of back pain patients. We at Semnur are very excited to receive fast track status from the FDA for our novel injectable gel formulation SP-102 in development and announce the start of our Phase 3 multi-center CLEAR Trial in Sciatica/Lumbar Radicular Pain (https://clinicaltrials.gov/ct2/show/NCT03372161?term=Semnur&recrs=ab&rank=1). In the U.S., more than 30 million people live with chronic low back and radicular sciatica pain, and many experience debilitating pain at moderate-to-severe levels with intolerance and/or inadequate response to current analgesic therapies such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). There is a great need for highly effective analgesic and anti inflammatory medications to provide patient relief without the toxicity and tolerability challenges of NSAIDs and opioids. Opioid prescriptions account for about 60 percent of the chronic pain market and commonly prescribed for low back pain but carry a well-known risk of abuse and misuse, underscoring the need for alternative pain therapies without the medical and societal challenges. In the United States, Semnur is planning to develop and commercialize product candidates, either through its own efforts or in conjunction with partners. Outside of the United States, Semnur anticipates commercializing these products on a worldwide basis through select regional partnerships.